IP, grants and governance issues in Dutch deeptech financing rounds
Category: InsightsIP, grants, strategic investors and governance issues in Dutch deeptech financing rounds
Quantum and deeptech scale-ups raise different legal implementation questions from ordinary software companies. Their value often sits in IP, research history, university or institute relationships, public funding, strategic collaborations, specialised employees, sensitive technology and long development timelines.
For founders and investors, the legal work is not limited to a term sheet or investment agreement. A Dutch deeptech financing round should test whether the company can show clean IP ownership, workable grant obligations, appropriate investor governance, controlled information rights and a structure that supports international expansion.
This article is part of Viotta’s US VC Terms & Dutch BV Structures Insights and related Dutch venture capital insights for deeptech companies.
Deeptech is not standard SaaS financing
Deeptech companies often have longer development cycles, higher capital needs, more technical diligence and more complex stakeholder groups. The company may have founders from universities, research institutes or corporate labs. It may rely on public funding, research collaborations, strategic partners or technology licences.
That makes legal implementation more important. Investors will not only review the cap table and financial model. They will ask whether the company owns or controls its core technology and whether any third party can restrict commercialisation, financing or exit.
A standard VC checklist is usually not enough.
IP ownership and chain of title
The first issue is IP ownership. Investors will want to know whether the Dutch company owns the core IP or has enforceable rights to use and commercialise it.
This requires review of founder assignments, employee IP clauses, contractor agreements, university or research institute arrangements, licence agreements, open-source components and background IP. If the technology was developed before incorporation, the transfer into the company must be clear.
For quantum and deeptech companies, vague IP ownership can become a major financing blocker.
Grants and public funding obligations
Many deeptech companies use grants, subsidies or public funding. These can be valuable, but they may come with reporting duties, spending restrictions, publication rules, location requirements, repayment triggers, consent rights or obligations that affect later financing or exit.
Founders sometimes treat grant terms as administrative. Investors usually do not. They want to know whether public funding terms restrict IP transfer, foreign ownership, relocation, commercialisation, licensing or a future sale.
Grant diligence should therefore be part of the financing workstream.
Strategic investors and information rights
Deeptech rounds often include strategic investors, corporate venture funds or investors with industry interests. Their involvement can add value, but also creates information sensitivity.
Information rights must be calibrated carefully. A strategic investor may want technical updates, milestone reporting and access to product roadmaps. The company must protect confidential information, trade secrets, IP, customer relationships and competitive positioning.
In some cases, technical information should be shared under stricter confidentiality, clean team arrangements or limited-access reporting
Governance and reserved matters
Deeptech investors often ask for stronger governance protections because development risk and capital needs are high. Reserved matters may cover new financing, IP transfers, material licensing, strategic partnerships, grant compliance, relocation of core activities, hiring or replacement of key technical personnel, and sale of material assets.
The list should remain practical. Investors need protection over value-critical decisions. Founders need freedom to manage technical development and commercial execution.
In a Dutch BV, these rights should be aligned with the shareholders’ agreement, articles of association and board procedures.
Sensitive technology and international expansion
Quantum and deeptech companies may operate in areas that attract regulatory, national security or export-control sensitivity. Not every deeptech company will trigger screening issues, but investors and founders should identify early whether the technology, investor base, customers or strategic partners create additional review requirements.
This matters especially for US or non-EU investors, strategic buyers, defence-related applications, dual-use technologies or cross-border transfers of IP and know-how.
Dutch legal implementation should therefore be coordinated with specialist regulatory, export control and tax advice where needed.
Future rounds and exit readiness
Deeptech companies often raise multiple rounds before commercial scale. The first significant financing should not create documents that make later rounds harder.
Liquidation preferences, anti-dilution, pro rata rights, information rights, strategic investor rights and grant-related restrictions should be modelled against future financing scenarios. The same applies to employee incentives and founder vesting.
Exit readiness also starts early. A buyer will review IP, grants, founder assignments, research arrangements and strategic investor rights. Those issues should be cleaned up before they become diligence problems.
Practical conclusion
Dutch quantum and deeptech scale-ups need financing documentation that reflects their real risk profile. IP ownership, grants, research relationships, strategic investors, sensitive technology, governance and future financing mechanics should be addressed before the round closes.
For founders, the goal is to secure capital without overburdening the company. For investors, the goal is to obtain protection that works under Dutch BV documentation and supports future growth, follow-on rounds and exit.
FAQ
Why are deeptech financing rounds legally different?
Because value often depends on IP, research history, grants, strategic partners, specialised employees and long development timelines.
What should investors review first?
IP ownership, founder and employee assignments, grant terms, research agreements, strategic investor rights, governance and future financing mechanics.
Can US investor terms be used in Dutch deeptech rounds?
Yes, but preferred shares, investor rights, information rights, anti-dilution and governance must be implemented through Dutch BV documentation.
About Dirk de Waard
Dirk de Waard is a Dutch corporate and M&A lawyer, partner at Venture Lawyers in Amsterdam, and advises Dutch deeptech companies, founders, investors and international counsel on VC financing rounds, Dutch BV governance, IP-related transaction issues, strategic investor rights and cross-border implementation.
Preparing a Dutch quantum or deeptech scale-up for investment?
A deeptech financing round should be built around the company’s real assets and risks: IP, grants, research arrangements, strategic investors, sensitive technology and future capital needs. Dutch BV documentation should support growth without creating avoidable diligence issues.
Dirk de Waard advises founders, deeptech scale-ups and investors on Dutch implementation of venture financing rounds. Contact dirk.dewaard@viottalaw.com to review the Dutch legal structure before a quantum or deeptech financing round.
